OTC Alerts

[Druides]

NEFT 5x10 Biotech RM looks like


Rich Rainey. Mr. Rainey has over twenty years of experience in forming, capitalizing and running biotechnology companies. Mr. Rainey has been affiliated with Avax Technologies for over fifteen years during which he helped the Company raise $60 million to fund drug development. At AVAX, he oversaw the launch of clinical studies and commercial activities in United States, Europe and Australia of the Company's cancer vaccines, while overseeing manufacturing and regulatory filings for Phase I, II and III protocols. He is a Certified Public Accountant in the Commonwealth of Pennsylvania and obtained his bachelors of science in accounting from the Pennsylvania State University.

Irwin L. Zalcberg. Mr. Zalcberg graduated from University of Illinois in 1970 with a BA in finance. He worked for Merrill Lynch between 1971-1974 as an account executive and on the floor of CBOE where he represented their proprietary risk arbitrage department. From 1975-1991, Mr. Zalcberg was an independent trader on the CBOE and held a Chicago Board of Trade mini seat. In addition, Mr. Zalcberg was member of the CBOE from 1973 to 2001. Mr. Zalcberg has helped manage $500M of family money, has held and continues to hold several board positions of both public and private companies, has started dozens of companies, and has been responsible for the exits of several private and public companies with a combined transaction value of almost $2B. He is also a survivor of Non-Hodgkin's Lymphoma.

Jayesh Mehta, MD. Dr. Mehta is a hematologist with over fifteen years of experience in blood cancers. He is an internationally-known expert in myeloma and hematopoietic stem cell transplantation. Dr. Mehta is co-inventor of several US patents covering the use of growth factors in myocardial infarction and stroke. He directs the Hematopoietic Stem Cell Transplant Program at Northwestern Memorial Hospital, Chicago. Dr. Mehta received his medical training at Bombay University, and specialized training/fellowship in hematologic malignancies and stem cell transplantation at Hadassah University Hospital, Jerusalem, Israel, and The Royal Marsden Hospital, UK.

David Moss. Mr. Moss is an experienced venture capitalist having over twenty years of experience in the life sciences, resource and technology space. Mr. Moss is Chairman and CEO of Re/Active Medical LTD a company focused on the disease of aging. Mr. Moss invested, helped finance and take public Mobivity Inc. (OTCBB: MFON) and Tonix Pharmaceuticals (NASDAQ: TNXP). He was recently a director of Armada Oil, Inc. (OTCBB: AOIL) and Pegasi Energy Resources Corporation (OTCBB: PGSI) and was responsible for both companies initial capital raises and public listings. He also is an investor, largest shareholder and sits on the Board of Managers of Sorteo Games LLC and is a board observer and investor for Reliant Business Services. Mr. Moss also acquired Digital Orchid, Inc. and renamed the company Sorteo Games, LLC which had over $26 million invested prior to his purchase. He also was instrumental in the purchase and restructuring of Mirapoint Software. Mirapoint is the first appliance-based email provider serving over 120 million corporate email accounts. He served as Managing Director, Corporate Finance, for Jesup Lamont Securities, where he advised companies on corporate strategy, financings, and business development. Previously, Mr. Moss served as Managing Partner at a Seattle-based venture capital firm, The Phoenix Partners with $110 million under management where he ran their healthcare portfolio. He holds an MBA from Rice University and a B.A. in Economics from the University of California, San Diego.

John T. Norton. Dr. Norton is an expert in cancer biology with 10 years of experience in cancer drug discovery & development. Dr. Norton is a co-inventor of Numonafide, one of Panther's clinical candidates. Dr. Norton received his PhD from Northwestern and is currently pursuing his MBA from the University of San Diego.